Your browser doesn't support javascript.
loading
Impact on follow-up strategies in patients with primary sclerosing cholangitis.
Bergquist, Annika; Weismüller, Tobias J; Levy, Cynthia; Rupp, Christian; Joshi, Deepak; Nayagam, Jeremy Shanika; Montano-Loza, Aldo J; Lytvyak, Ellina; Wunsch, Ewa; Milkiewicz, Piotr; Zenouzi, Roman; Schramm, Christoph; Cazzagon, Nora; Floreani, Annarosa; Liby, Ingalill Friis; Wiestler, Miriam; Wedemeyer, Heiner; Zhou, Taotao; Strassburg, Christian P; Rigopoulou, Eirini; Dalekos, George; Narasimman, Manasa; Verhelst, Xavier; Degroote, Helena; Vesterhus, Mette; Kremer, Andreas E; Bündgens, Bennet; Rorsman, Fredrik; Nilsson, Emma; Jørgensen, Kristin Kaasen; von Seth, Erik; Cornillet Jeannin, Martin; Nyhlin, Nils; Martin, Harry; Kechagias, Stergios; Wiencke, Kristine; Werner, Mårten; Beretta-Piccoli, Benedetta Terziroli; Marzioni, Marco; Isoniemi, Helena; Arola, Johanna; Wefer, Agnes; Söderling, Jonas; Färkkilä, Martti; Lenzen, Henrike.
Afiliação
  • Bergquist A; Department of Medicine Huddinge, Unit of Gastroenterology and Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Weismüller TJ; European Reference Network for Hepatological Diseases, Stockholm, Sweden.
  • Levy C; Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany.
  • Rupp C; Division of Digestive Health and Liver Diseases, University of Miami, Florida, USA.
  • Joshi D; Schiff Center for Liver Diseases, University of Miami, Florida, USA.
  • Nayagam JS; Department of Gastroenterology, Infectious Diseases, Intoxication, Heidelberg University Hospital, Heidelberg, Germany.
  • Montano-Loza AJ; Institute of Liver Studies, King's College Hospital, London, United Kingdom.
  • Lytvyak E; Institute of Liver Studies, King's College Hospital, London, United Kingdom.
  • Wunsch E; Division of Gastroenterology and Liver Unit, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Milkiewicz P; Division of Gastroenterology and Liver Unit, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Zenouzi R; Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.
  • Schramm C; Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.
  • Cazzagon N; Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.
  • Floreani A; Department of Medicine and Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Liby IF; Department of Medicine and Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Wiestler M; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • Wedemeyer H; European Reference Network on Hepatological Disease, European Reference Network for Hepatological Diseases, Azienda Ospedaliera-Università di Padova, Padova, Italy.
  • Zhou T; Studiosa Senior University of Padova, Italy and Scientific Consultant IRCCS Negrar, Verona, Italy.
  • Strassburg CP; Department of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Rigopoulou E; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Dalekos G; European Reference Network for Hepatological Diseases, Hannover, Germany.
  • Narasimman M; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Verhelst X; European Reference Network for Hepatological Diseases, Hannover, Germany.
  • Degroote H; Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany.
  • Vesterhus M; Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany.
  • Kremer AE; Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.
  • Bündgens B; Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.
  • Rorsman F; Schiff Center for Liver Diseases, University of Miami, Florida, USA.
  • Nilsson E; Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.
  • Jørgensen KK; Ghent Liver Research Center, Ghent University, Ghent, Belgium.
  • von Seth E; European Reference Network for Hepatological Diseases, Ghent, Belgium.
  • Cornillet Jeannin M; Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.
  • Nyhlin N; Ghent Liver Research Center, Ghent University, Ghent, Belgium.
  • Martin H; European Reference Network for Hepatological Diseases, Ghent, Belgium.
  • Kechagias S; Norwegian PSC Research Centre, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Wiencke K; Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Werner M; Department of Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.
  • Beretta-Piccoli BT; Department of Medicine 1, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.
  • Marzioni M; Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
  • Isoniemi H; Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Arola J; Department of Gastroenterology and Hepatology, University Hospital, Uppsala, Sweden.
  • Wefer A; Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Söderling J; Gastroenterology Clinic, Skåne University Hospital, Sweden.
  • Färkkilä M; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
  • Lenzen H; Department of Medicine Huddinge, Unit of Gastroenterology and Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Liver Int ; 43(1): 127-138, 2023 01.
Article em En | MEDLINE | ID: mdl-35535655
BACKGROUND & AIMS: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies in PSC with the hypothesis that regular imaging improves survival. METHODS: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last clinical follow-up alive. The primary endpoint was all-cause mortality. RESULTS: A broad variety of different follow-up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow-up, was 0.61 (0.47-0.80) for scheduled imaging with and without ERCP; 0.64 (0.48-0.86) for US/MRI and 0.53 (0.37-0.75) for follow-up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high-grade dysplasia as a time-dependent covariate, HR 0.57 (0.44-0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow-up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed. CONCLUSIONS: Follow-up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangite Esclerosante / Colangiocarcinoma Tipo de estudo: Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangite Esclerosante / Colangiocarcinoma Tipo de estudo: Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article